Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Responding With Evidence and Access for Childhood Headaches
Recruiting
This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will b... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/11/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Recruiting
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Gender:
ALL
Ages:
Between 29 days and 17 years
Trial Updated:
06/11/2025
Locations: Children's Hospital of Philadelphia (CHOP) ( Site 0004), Philadelphia, Pennsylvania
Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Recruiting
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Gender:
ALL
Ages:
All
Trial Updated:
06/11/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Generalized Myasthenia Gravis, gMG
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Recruiting
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/11/2025
Locations: Children's Hospital of Philadelphia (CHOP) ( Site 1608), Philadelphia, Pennsylvania
Conditions: Pulmonary Arterial Hypertension
Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness
Recruiting
The purpose of this study is to confirm the safety, performance and effectiveness of Stryker's PEEK Customized Implants when used for the augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton. The study is designed as a prospective, multi-center trial with a long-term follow-up (24 months) of study participants.
Gender:
ALL
Ages:
42 months and above
Trial Updated:
06/11/2025
Locations: Lewis Katz School of Medicine at Temple University, 3401 North Broad Street, Philadelphia, Pennsylvania
Conditions: Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Brain Connections for Arm Movement After Stroke
Recruiting
The purpose of this study is to use Transcranial Magnetic Stimulation (TMS) while subjects are making reaching movements in a robotic arm device in order to discover how different brain areas control movement before and after stroke and when these brain areas are most sensitive to TMS.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
06/11/2025
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Stroke, Brain Disease, Central Nervous System Diseases, Nervous System Diseases, Cardiovascular Diseases
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Altimmune Clinical Study Site, Philadelphia, Pennsylvania
Conditions: Alcohol Use Disorder (AUD)
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
Recruiting
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
Gender:
FEMALE
Ages:
Between 55 years and 80 years
Trial Updated:
06/10/2025
Locations: Altoona Center for Clinical Research, Duncansville, Pennsylvania
Conditions: Postmenopausal Osteoporosis
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Recruiting
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: UPMC Vision Institute, Pittsburgh, Pennsylvania
Conditions: Retinitis Pigmentosa, Choroideremia
Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke
Recruiting
The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are: 1. What regions of the brain's sensory systems show changes in their activity related to speech? 2. To what extent do these regions help listeners detect and correct speech errors? 3. What is the role of the cerebellum (a part of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Stroke, Cerebellum
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes.... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Recruiting
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Gender:
ALL
Ages:
1 year and below
Trial Updated:
06/10/2025
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Lymphoblastic Leukemia